AOD-9604 research guide for Ås. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Ås searching for AOD-9604, the key fact to understand is that this compound is available only through an online research supply market. This concentration of supply in online vendors is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. What genuinely separates top AOD-9604 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Ås researcher needs to evaluate quality systematically.
Understanding AOD-9604 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Ås researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade AOD-9604
The most consistent path to quality AOD-9604 is engaging research communities before vendor sites — peptide forums maintain informal vendor reputation databases that are more reliable than search results. A COA for AOD-9604 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. The combination of community consensus and independent COA review is the most reliable sourcing approach — community feedback surfaces patterns individual COA review misses, and vice versa. For Ås researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Ås
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — equivalent to 25mcg per unit on an insulin syringe. Endotoxin testing in the AOD-9604 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no pricing advantage justifies skipping this verification. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any AOD-9604 protocol that makes anomalous results interpretable.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
